Table 4 Meta-analyses on the hazard ratio of the overall survival of the subgroups of HPV^+/− and p16^+/−.

HPV⁻/p16⁻ versus HPV⁺/p16⁺

6

425

206/219

0.15 (0.15–0.15); p < 0.0001

0.19 (0.05–0.69); p = 0.0122

tau² = 2.68; H = 949.3 (945.0–953.6) I² = 100%; p < 0.0001

25,30,32,33,37,43

HPV⁺/p16⁺ versus HPV^-/p16^-

5

1768

971/797

4.60 (4.51–4.70); p < 0.0001

3.49 (1.93–6.31); p < 0.0001

tau² = 0; H = 9.1 (7.6–11.0) I² = 98.8%; p = 0.6005

24,26,28,34,47

HPV⁺/p16⁺ versus HPV⁻/p16⁺

3

1045

900/145

2.70 (2.59–2.82); p < 0.0001

3.3007 (1.4004; 7.7797); p < 0.0001

tau² < 0.0001; H = 1.0 (1.0–1.0); I² = 0%; p = 0.90

24,34,47

HPV⁻/p16⁻ versus HPV⁻/p16⁺

2

75

55/20

1.20 (0.73–1.99); p = 0.48

1.20 (0.73–1.99); p = 0.48

tau² = 0; H = 1.0; I² = 0%; p = 0.89

30,31

HPV⁺/p16⁺ versus HPV⁺/p16^-

4

1080

925/80

4.09 (3.59–4.67) p < 0.0001

4.09 (3.59–4.67); p < 0.0001

tau² = 0; H = 1.0 (1.0–1.0); I² = 0%; p = 0.97

24,26,34,47

HPV⁻/p16⁻ versus HPV⁻/p16⁻

4

191

106/85

0.619 (0.60–0.64); p < 0.0001

0.76 (0.46–1.26); p = 0.29

tau² = 0.20; H = 11.3 (9.4–13.6); I² = 99.2%; p < 0.0001

30,31,33,43